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Isolated limb perfusion for unresectable extremity cutaneous
squamous cell carcinoma; an effective limb saving strategy
Eva A. Huis in ’t Veld1,2, Dirk J. Grünhagen3, Jan P. Deroose2,3, Tamar E. C. Nijsten4, Michel W. J. M. Wouters2, Cornelis Verhoef3,
Winan J. van Houdt1,2 and Andrew J. Hayes1
BACKGROUND: A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of
this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP)
as a limb saving strategy for locally advanced extremity cSCC.
METHODS: A retrospective search from prospectively maintained databases, at two tertiary referral centers, was performed to
identify patients treated with TM-ILP for locally advanced cSSC of an extremity between 2000 and 2015.
RESULTS: A total of 30 patients treated with TM-ILP for cSCC were identiﬁed, with a median age of 71 years (36–92) and 50%
female. Response could not be evaluated in 3 patients. After a median follow up of 25 months, the overall response rate was 81%
(n= 22), with 16 patients having a complete response (CR, 59%). A total of 7 patients developed local recurrence, with a median
time to recurrence of 9 months (Interquartile Range 7–10). Progressive disease was observed in 5 patients (19%). Limb salvage rate
was 80%. The overall 2-year survival was 67%.
CONCLUSIONS: TM-ILP should be considered as an option in patients with locally advanced cSCC in specialised centers, resulting in
a high limb salvage rate.
British Journal of Cancer (2018) 119:429–434; https://doi.org/10.1038/s41416-018-0149-z
INTRODUCTION
Non-melanoma skin cancer (NMSC) is the most frequent human
malignancy1,2 with an increasing incidence reaching epidemic
proportions among Caucasians in Europe, America and Australia.3–8
Approximately 80% of all NMSC are basal cell carcinomas (BCC)
and 20% are cutaneous squamous cell carcinomas (cSCC).6–9
Usually cSCC presents as a localised lesion, for which various
treatment strategies are available: wide surgical excision, Mohs
surgery, cryosurgery, and radiation therapy. Margins of resection
are an important prognostic factor for outcome10 and the primary
aim of surgery is to remove the tumour in total with adequate
margins. However some patients will present with locally
advanced disease. In such locally advanced cases, a radical
resection to achieve negative surgical margins may lead to serious
loss of limb function, or may even require an amputation.
Regional chemotherapy by hyperthermic isolated limb perfu-
sion was introduced as a therapy to treat advanced extremity
malignancies either as a standalone treatment or as a neo
adjuvant treatment to downsize a malignancy and facilitate
function preserving surgery.11,12 Several reports show excellent
response rates with tumour necrosis factor α (TNF) and melphalan
based isolated limb perfusion (TM-ILP) for both melanomas with
multiple in transit metastases and for locally advanced soft tissue
sarcomas.11,13–15 Likewise, large series show that TM-ILP is a safe
procedure with only a limited local toxicity without severe
systemic toxicity.16 These observations led to the exploration of
ILP for locally advanced cSCC of the extremities. This study aims to
evaluate the effectiveness of TM-ILP as a limb saving strategy for
locally advanced cSCCs in the extremities.
METHODS
Patients
Between 2000 and 2015, all patients treated with TM-ILP for locally
advanced cSCC were identiﬁed from a prospectively maintained
database in one of the two tertiary referral hospitals: Erasmus MC—
Cancer Institute, Rotterdam, the Netherlands, and Royal Marsden
Hospital, London, United Kingdom. All patients were considered to be
surgically treatable only by amputation or function disrupting ablative
surgery because the extent of tumour affecting the limb. Unresect-
ability of the tumour was based on the following factors: size,
multifocality, number of recurrences, and tumour location (adherent
to bones, blood vessels or nerves). All patients were discussed in a
multidisciplinary tumour board. The majority of patients had chronic
infected fungating tumours, and therefore almost all patients
underwent TM-ILP with prophylactic systemic antibiotics.
Perfusion
The ILP technique has been described extensively before.17
Brieﬂy, after heparinisation, the surgeon isolated the targeted
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vessels from the systemic circulation and cannulated the
vessels with silastic cannulae. The surgical approach for
cannulation could either be at the inguinal, femoral, axillary,
or brachial level depending on the location of the tumour. To
prevent leakage a pneumatic tourniquet was used to compress
collateral vessels. Leakage from the isolated circulation to the
systemic circulation was measured continuously using techne-
tium labelled albumin. A dose of 1 to 3 mg (arm) or 1 to 3 mg
(leg) of recombinant TNF was injected as a bolus. The dose of
melphalan raged between 50 and 80 mg for the perfusion of a
leg and between 25 and 60 mg for an arm based on volume of
the limb or body weight.16 After the perfusion, the limb was
washed out.
Toxicity
Acute regional toxicity after perfusion was classiﬁed according to
Wieberdink et al.18 Regional toxicity and systemic complications
were evaluated during the hospital stay or during follow up visits.
Outcome
The primary outcome measure was response to TM-ILP. Response
was measured by clinical examination and scored following World
Health Organisation criteria.19 Time to local progression, systemic
disease and overall survival were deﬁned as time from ILP to the
event.
The secondary outcome measure was limb salvage after TM-ILP.
TM-ILP could potentially be a curative treatment or a neoadjuvant
therapy to downsize a tumour prior to radical function preserving
resection. Both of these approaches were considered to be limb
salvage strategies.
Statistical analysis
In this retrospective review, survival analyses were performed
using the Kaplan Meier method. Differences between groups were
assessed by the Log-rank test, T-tests and Fisher exact tests. A p-
value of 0.05 was considered signiﬁcant. Confounders for local
progression and overall survival (OS) were identiﬁed using
univariate analysis. Only confounders with a p-value below 0.1
were subsequently included in a multivariate Cox regression.
Factors explored were: age, gender, hospital of treatment, site and
size of the tumour (<5 cm, or >5 cm). IBM SPSS statistics 24 was
used for the statistical analyses.
RESULTS
Patients
A total of 30 patients were treated with TM-ILP of which 15 (50%)
were female. Median age at time of TM-ILP was 71 (Interquartile
Range [IR] 62–79). Median follow up was 25 months (IR 10–36).
TM-ILP was offered in 18 patients with primary disease (60%), in 10
patients with local recurrent cSCC (33%), and two patients were
known to have systemic disease and underwent a palliative ILP
(7%). Patient, tumour, and treatment characteristics are sum-
marised in Table 1.
Treatment outcome
Response could be evaluated in 27 patients. In three patients
response could not be evaluated because of, amputation (n= 1),
or death (n= 2) within 3 months after ILP.
The overall response (OR) rate of these 27 patients was 81% (n
= 22). Sixteen patients had a complete response (CR, 59%) and six
patients had a partial response (PR, 22%). An example of a
complete response is depicted in Fig. 1. Five patients (19%) had
progressive disease (PD) within 3 months after TM-ILP. No
differences in tumour size (p= 1000), stage of disease (p=
0.248), number of tumours (p= 0.246) and tumour location (p=
0.263) were found between the different response groups
(Table 2).
Surgical intervention
Of all 30 patients, at least 19 patients were candidates for
amputation before ILP. Of these patients, 13 patients did not need
surgical intervention after ILP (68%), 1 patient needed resection
(5%) and 5 needed amputations (26%).
Analysing all 30 patients, 12 patients eventually needed surgical
intervention after TM-ILP (40%), which consisted of resection of
tumour in 5 patients (17%), and amputation in 6 patients (20%)
(Fig. 2). One patient (3%) needed surgical intervention but refused.
Of the ﬁve patients who underwent a limb conserving resection
of residual or remaining tumour, two patients underwent
resection of residual tumour and the tumour was found to be
100% necrotic on histopathological analysis. Both of these
patients were classiﬁed as CR. Two patients had PD with already
metastatic disease at time of ILP. For these patients ILP was done
with palliative intent because of intractable pain and/or
Table 1. Patients, tumour and treatment characteristics
N (%) Median (range)
Gender
Male 15 (50)
Female 15 (50)
Age
In years 71 (36–92)
Sizea
≤5 cm 10 (38)
>5 cm 16 (62)
Site
Arm 3 (10)
Hand or wrist 5 (17)
Leg 16 (53)
Ankle or foot 7 (20)
Number of tumours
Unifocal 24 (80)
Multifocal 6 (20)
Disease stage cSCC
at presentation
Primary 18 (60)
Recurrent 10 (33)
Metastatic 2 (7)
Concurrent
metastasis
None 25 (83)
Lymph node 3 (10)
Distant 2 (7)
Surgical approach
Axillary 3 (10)
Brachial 6 (20)
Femoral 20 (67)
Iliac 1 (3)
Doses
TNFb (mg) 2 (1–3)
Melphalanb (mg) 60 (25–80)
Hospital stay
In days 6 (1–72)
cSCC cutaneous squamous cell carcinoma, TM-ILP TNF and melphalan
based isolated limb perfusion. aunknown size (n= 4). bmedian dose in mg
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uncontrollable wounds, but due to progression surgery was
unavoidable. One patient had a clinical PR and underwent a
surgical resection of residual tumour which demonstrated viable
tumour on histopathological analysis.
Of the 6 patients who underwent an amputation after TM-ILP,
one patient had an initial CR but subsequently needed amputa-
tion after development of local recurrence. After resection of the
recurrence this patients suffered from severe wound healing
Pre-ILP TM-LLP 2 months after TM-ILP 
Ongoing response 9 months after TM-ILP
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Fig. 1 Course of a complete response of the lower leg. Ongoing response 9 months after TM-ILP. TM-ILP TNF and melphalan-based isolated
limb perfusion
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problems and amputation was unavoidable. Three patients had an
amputation because of PD, and one patient had a PR but still
needed amputation. Finally, one patient needed amputation due
to ischemia. The median time between TM-ILP and amputation in
these 6 patients was 3 months (range 0–9).
Local progression
Of the 27 patients were response could be evaluated, ﬁve patients
(19%) showed no response to TM-ILP and had immediate PD. Of
all 30 patients, another 7 patients (23%) developed local
progressive disease during follow up. The median time to local
progression for these 7 patients was 9 months (IR 7–10) (Table 3).
The local progression free survival (PFS) was signiﬁcantly longer in
the CR group, compared to the PR group (Log-rank, p= 0.018),
whereby the median PFS for both groups was not reached. None
of the following factors were associated with duration of PFS: age
(p= 0.216), gender (p= 0.560), hospital (p= 0.187), site (p=
0.862), and size of the tumour (<5 cm, or >5 cm, p= 0.939).
Systemic metastasis
A total of 3 patients in this cohort had lymph node metastases at
time of ILP (10%) and were treated with lymph node dissection
concurrent with ILP. In addition, 3 more patients (10%) developed
lymph node metastases in the follow up and were treated with
lymph node dissection with a median time to lymph node
metastases of 4 months (range, 0–9) (Table 3). Systemic
metastases were present in two patients (7%) at time of ILP,
while two more patients (7%) developed systemic disease during
follow up: 3 and 21 months after ILP (Table 3).
Table 2. Patient characteristics per response to ILP
CR (n, %) PR
(n, %)
PD
(n, %)
p-value
Size 1.000F
<5 cm 6 (43) 2 (50) 2 (40)
>5 cm 8 (57) 2 (50) 3 (60)
Number of tumours 0.246F
Unifocal 13 (81) 5 (83) 3 (60)
Multifocal 3 (19) 1 (17) 2 (40)
Disease stage cSCC at
presentation
0.248F
Primary 10 (63) 4 (67) 2 (40)
Recurrence 2 (12) 1 (17) 1 (20)
Multiple recurrence 4 (25) 1 (17) 2 (40)
Location 0.263F
Arm 2(13) 0 (0) 1 (20)
Wrist or hand 2 (13) 2 (33) 0 (0)
Leg 7 (44) 3 (50) 4 (80)
Foot or ankle 5 (31) 1 (17) 0 (0)
F Fisher exact test, CR Complete response, PR Partial response, PD
progressive disease, cSCC cutaneous Squamous cell carcinoma
ILP for
unresectable SCC
Response assessed
after ILP
Complete
response Partial response
Progressive
disease
No surgerySurgeryNo surgerySurgeryNo surgerySurgery
Amputation Resection Amputation Resection Amputation Resection
n=30
n=27 (100%)*
n=16 (59%) n=6 (22%) n=5 (19%)
n=4 (15%)n=2 (7%)n=12 (44%)n=4 (15%)
n=1 (4%) n=3 (11%) n=2 (7%) n=0 (0%) n=3 (11%) n=2 (7%)
n=5 (19%) n=0 (0%)
Fig. 2 Consort diagram of patients per response group and surgical intervention. *In three patients response could not be evaluated
Table 3. Response, local recurrence and systematic disease
Type of responsea Patients
(n, %)
Local progression
(n, %)
Months to local progression
(median, range)
Metastatic diseaseb
(n, %)
Months to metastatic disease
(median, range)
Complete response 16 (59) 4 (25) 9 (9–22) 4c (25) 0 (0–21)
Partial response 6 (22) 3 (50) 4 (2–6) 3 (33) 3 (3–9)
Progressive disease 5 (19) N/A 0 (0–0) 3d (60) 0 (0–4)
Overall response 22 (81) 7 (23) 9 (2–22) 10 (32) 3 (0–21)
afor 3 patients response could not be assessed. bmetastatic disease includes regional and distant metastasis. c3 patients already had metastatic disease at time
of ILP. d2 patients already had metastatic disease at time of ILP
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Overall survival
Eighteen patients were alive at last follow up (60%) with a median
follow up for this particular group of 30 months (IR 18–38). In 14
patients (47%) there was no evidence of disease at last follow-up.
Twelve patients (40%) died during follow up, of whom 6 (20%)
died of advanced disease, 2 (7%) of complications after surgery,
and 4 (13%) of reasons not related to cSCC. Median OS was
54 months (95% CI: 20.4–87.6), with a 2 year survival of 67%.
Gender (p= 0.187), hospital (p= 0.748), site of cSCC (p= 0.241),
and size of the tumour (<5 cm, or >5 cm, p= 0.370) did not
inﬂuence overall survival.
Complications
The vast majority of patients in this series did not experience
serious local toxicity. In 25 patients (83%) Wieberdink I or II was
observed and in four patients (13%) Wieberdink III. One patient
(3%) underwent an amputation 9 days following TM-ILP
(Wieberdink V) due to ischemia. Leakage to the systemic
circulation was minimal in all procedures, in only one case a
leakage of 5% was noted, while in all other cases leakage was 2%
or lower. The 30 mortality following TM-ILP for advanced cSSC
was 0, however, two patients died 66 and 71 days after perfusion.
The ﬁrst patient was admitted to the Intensive Care Unit with
respiratory distress after his operation and eventually died of
pneumonia and respiratory failure. This patient had severe
comorbidity, including severe chronic pulmonary obstructive
disease and pre-existing diabetic complications (renal failure and
hypertension). The procedure of the second patient was
complicated due to a rupture of the brachial artery that was
cannulated for TM-ILP. The patient was re-operated in an outside
hospital and a vascular prosthesis was inserted. The patient died
two months after TM-ILP of septic complications caused by an
infected vascular prosthesis.
DISCUSSION
This unique multicentre experience of 30 TM-ILPs as treatment for
locally advanced cSCC and demonstrates that TM-ILP is a valuable
limb saving strategy in selected patients who would otherwise
need an amputation or function disrupting ablative surgery. To
our knowledge, this is the largest report on the outcome of ILP for
locally advanced cSCC. With an overall response rate of 81%, a CR
rate of 59%, and a limb salvage rate of 80%, this data shows that
ILP is an effective treatment to obtain local control for locally
advanced cutaneous squamous skin carcinoma. Almost half of the
patients were free of disease at the end of follow up (n= 14, 47%).
Reports in the literature of oncological outcomes for advanced
unresectable cSCC treated by ILP or other modalities are rare. One
small study reports a series of 12 ILPs treated at multiple centres
for cSCC with comparable results to this study (CR of 67% and 75%
limb salvage rate).20
Other treatment modalities described for advanced cSCC at any
site include conventional cytotoxic chemotherapy, newer systemic
therapies, radiotherapy, and combinations of these modalities.21–30
The are a number of small case series of patients with advanced
cSCC treated with cytotoxic chemotherapy usually involving
cisplatin.22,24,25 Only 2 studies included more than 10 patients,
one reporting a CR in 4 out of 14 patients using a Cisplatin, 5-FU
and bleomycin regime22, and another reporting a PR rates of 56%
and 47% using either platinum or taxane based chemotherapies
respectively. Immunotherapy is mostly described using interferon
alpha with or without chemotherapy, with the highest CR of 50%
when combining Retinoid acid, interferon alpha and Cisplatin.23–26
More recently targeted therapies have been uses for advanceds
cSCC.25,28–30 Two large studies evaluated the effectiveness of
cetuximab and panitumumab in locally advanced and metasta-
sised cSCC.28,30 Maubec et al. found a CR of 6%, a PR of 26% and
an overall survival 8.1 months with cetuximab, with 47% of the
patients having locally advanced cSCC.28 Foote et al. found an OR
of 31% with panitumumab, including the 13 patients with locally
advanced cSCC.30
There is very limited data regarding durable responses of
radiotherapy as single treatment in locally advanced cSCC,
however adjuvant radiotherapy can signiﬁcantly improve survival
in patients with lymph node metastases.23
Although the side effects of the TM-ILPs were low in this cohort,
we did observe two (7%) in hospital deaths within 3 months after
TM-ILP which is rare for ILP treatment. One of these patients died
of pulmonary complications, while this patient was known to have
severe co-morbidity including diabetes and severe COPD. Given
the low leakage rate it is unlikely that his postoperative respiratory
problems were caused or exacerbated by systemic leakage of the
drugs, although we cannot rule this out completely. The second
patient died of a complication that was directly attributable to ILP
(sepsis subsequent to an infected arterial graft after an rupture of
the brachial artery at the site of cannulation). Experience from
larger series of ILP for the treatment of sarcoma and melanoma
indicate that the mortality rate associated with ILP is less than
1%15–17,31–34 Of interest, both patients were classiﬁed as American
Society of Anesthesiologists physical status classiﬁcation (ASA)—
three patients, and both patients were treated in the early stages
of this ILP treatment. Both centres are far more experienced with
the procedure now than 15 years ago, and patient selection
is more strict when it comes to patients with (severe) co-
morbidity.
This study is limited by the relatively small number of patients,
and therefore the results should be read with caution. Also,
outcome could not be assessed in 3 out of 30 patients potentially
leading to a bias in response rates. Nevertheless even with these
caveats the response rates remain higher than other reported
treatments.21–30
Of interest, the agents used for ILP are derived from the
melanoma ILP protocol. In literature, results of ILP are reported
combining doxorubicin with TNF-a showing similar results.35,36
These results are promising, and exploration of other chemother-
apeutic agents to possibly achieve even higher response rates
could be interesting for the future.
In conclusion, TM-ILP is an effective treatment option for
patients with locally advanced cSCC based on this study.
Altogether, TM-ILP should be considered as an option in locally
advanced cSCC patients.
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